GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Trevena TRVN · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.01

0.00%

Close of 27 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Trevena — daily TRVN Delayed
Market value
$5,654
Last close × shares
Volume
210
Shares, 27 Oct 2026

About Trevena

Its shares trade under the ticker TRVN. It has been listed since 31 January 2014. In the fiscal year to 31 December 2023, it reported revenue of $3.1m and a net loss of $40.3m. At that date it held total assets of $40.6m and shareholders' equity of −$7.7m.

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. The company is headquartered in Chesterbrook, Pennsylvania. The company went IPO on 2014-01-31. The firm is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. The company is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. The company is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. The company is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Figures and description from our data supplier, not checked against the company's own report.

More about Trevena →

How it makes its money

Revenue, year to 31 Dec 2021

  • Product revenue $498,000 · 87.8%
  • License revenue $100,000 · 17.6%

Latest on Trevena

Our reporting

We have not reported on Trevena yet.

Next results

3 Mar 2027

Due on 3 Mar 2027. Analysts expect earnings of -46.88 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Trevena's ticker?

Trevena trades as TRVN on its US listing, under ISIN US89532E3071.

What was Trevena's last closing price?

0.01 on 27 Oct 2026. The figure is in USD and is never converted.

When does Trevena next report results?

Results are expected on 3 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.